Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)

NCT00061945 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00061945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00061945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2003
Completion date
October 31, 2012
Enrollment
302 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute undifferentiated leukemia, b-cell adult acute lymphoblastic leukemia, b-cell childhood acute lymphoblastic leukemia, l1 adult acute lymphoblastic leukemia, l1 childhood acute lymphoblastic leukemia, l2 adult acute lymphoblastic leukemia, l2 childhood acute lymphoblastic leukemia, philadelphia chromosome negative adult precursor acute lymphoblastic leukemia, philadelphia chromosome positive adult precursor acute lymphoblastic leukemia, philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia, t-cell adult acute lymphoblastic leukemia, t-cell childhood acute lymphoblastic leukemia, untreated adult acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia